230 related articles for article (PubMed ID: 36283150)
21. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
[TBL] [Abstract][Full Text] [Related]
22. JCV detection in multiple sclerosis patients treated with natalizumab.
Sadiq SA; Puccio LM; Brydon EW
J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
[TBL] [Abstract][Full Text] [Related]
23. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.
Major EO
Annu Rev Med; 2010; 61():35-47. PubMed ID: 19719397
[TBL] [Abstract][Full Text] [Related]
24. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
25. Progressive multifocal leukoencephalopathy in multiple sclerosis.
Chalkley JJ; Berger JR
Curr Neurol Neurosci Rep; 2013 Dec; 13(12):408. PubMed ID: 24136456
[TBL] [Abstract][Full Text] [Related]
26. AIDS-associated progressive multifocal leukoencephalopathy : current management strategies.
Roberts MT
CNS Drugs; 2005; 19(8):671-82. PubMed ID: 16097849
[TBL] [Abstract][Full Text] [Related]
27. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
[TBL] [Abstract][Full Text] [Related]
28. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
29. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Carruthers RL; Chitnis T; Healy BC
Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
[TBL] [Abstract][Full Text] [Related]
30. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.
Tan CS; Koralnik IJ
Lancet Neurol; 2010 Apr; 9(4):425-37. PubMed ID: 20298966
[TBL] [Abstract][Full Text] [Related]
31. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Baldwin KJ; Hogg JP
Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
[TBL] [Abstract][Full Text] [Related]
32. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
33. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
[TBL] [Abstract][Full Text] [Related]
34. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444
[TBL] [Abstract][Full Text] [Related]
36. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?
Diotti RA; Nakanishi A; Clementi N; Mancini N; Criscuolo E; Solforosi L; Clementi M
Clin Dev Immunol; 2013; 2013():967581. PubMed ID: 23878587
[TBL] [Abstract][Full Text] [Related]
37. TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy.
Mahler C; Schumacher AM; Unterrainer M; Kaiser L; Höllbacher T; Lindner S; Havla J; Ertl-Wagner B; Patzig M; Seelos K; Neitzel J; Mäurer M; Krumbholz M; Metz I; Brück W; Stadelmann C; Merkler D; Gass A; Milenkovic V; Bartenstein P; Albert NL; Kümpfel T; Kerschensteiner M
Brain; 2021 Oct; 144(9):2683-2695. PubMed ID: 33757118
[TBL] [Abstract][Full Text] [Related]
38. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.
Cortese I; Reich DS; Nath A
Nat Rev Neurol; 2021 Jan; 17(1):37-51. PubMed ID: 33219338
[TBL] [Abstract][Full Text] [Related]
39. Immunology of progressive multifocal leukoencephalopathy.
Jelcic I; Jelcic I; Faigle W; Sospedra M; Martin R
J Neurovirol; 2015 Dec; 21(6):614-22. PubMed ID: 25740538
[TBL] [Abstract][Full Text] [Related]
40. Natalizumab: risk stratification of individual patients with multiple sclerosis.
Tur C; Montalban X
CNS Drugs; 2014 Jul; 28(7):641-8. PubMed ID: 24942634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
